-
Mashup Score: 1
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods Using EULAR standardised operating procedures, the EULAR task force undertook a…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0A modified renal risk score for Chinese patients with antineutrophil cytoplasmic antibody-associated vasculitis - BMC Medicine - 1 year(s) ago
Background The renal risk score (RRS) is a useful tool to predict end-stage renal disease (ESRD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The current study aimed to validate the predictive performance of RRS and to further modify this model in Chinese AAV patients. Methods Two hundred and seventy-two patients diagnosed with AAV confirmed by renal…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A modified #renal #riskscore for Chinese patients with antineutrophil cytoplasmic antibody #ANCA-associated vasculitis #AAV Online prediction tool published with the article - https://t.co/W6M9giUOrv #kidney #rheumtiwtter #nephtwitter https://t.co/maPz1wqnWH
-
-
Mashup Score: 0Source: link.springer.comCategories: Latest Headlines, RheumatologyTweet
-
🔥Check out the results of the NEW survey on various physicians’ perceptions regarding #ANCA #vasculititis across countries 👉https://t.co/oiGdU7bfSv https://t.co/Ffs0uKv6gH
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
REVIEW The complement system in antineutrophil cytoplasmic antibody-associated #vasculitis: pathogenic player and therapeutic target: Current Opinion in #Rheumatology https://t.co/Hv6XJZEjHa. #AAV #ANCA #autoimmune #rheum #C5a #Avacopan
-
-
Mashup Score: 0Rituximab for Older Patients With Antineutrophil Cytoplasm Antibody–Associated Vasculitis - 2 year(s) ago
This cohort study assesses outcomes associated with the use of rituximab as induction and/or maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody–associated vasculitis.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In this cohort study, (#ANCA)-associated vasculitis receiving rituximab + high-dose glucocorticoids as induction therapy had a high serious infection rate. @ThietartS https://t.co/lj2PegeKni
-
-
Mashup Score: 2ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification - 2 year(s) ago
Pauci-immune necrotizing glomerulonephritis (PING) is usually associated with the presence of antineutrophil cytoplasmic antibodies (ANCA). However, a minority (2%-3%) of patients with PING do not have detectable ANCA. We assessed the clinical spectrum and outcome of patients with ANCA-negative PING.
Categories: Latest Headlines, NephrologyTweet-
ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification https://t.co/nssk7aa1PL (FREE temporarily) @RonsinCharles @LudivineLebour1 @MoglieQuintrec @karine_renaudin #AKI #ANCA #VisualAbstract https://t.co/9uANBf3qhZ
-
-
Mashup Score: 5DEFINE_ME - 2 year(s) agoSource: secure.jbs.elsevierhealth.comCategories: Latest Headlines, NephrologyTweet
-
ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification https://t.co/pSB2zNPn9V (FREE temporarily) @RonsinCharles @LudivineLebour1 @MoglieQuintrec @karine_renaudin #AKI #ANCA #VisualAbstract https://t.co/HM7FfXFli4
-
-
Mashup Score: 0ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification - 2 year(s) ago
Pauci-immune necrotizing glomerulonephritis (PING) is usually associated with the presence of antineutrophil cytoplasmic antibodies (ANCA). However, a minority (2%-3%) of patients with PING do not have detectable ANCA. We assessed the clinical spectrum and outcome of patients with ANCA-negative PING.
Categories: Latest Headlines, NephrologyTweet-
ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification https://t.co/XCyry3BYBm @RonsinCharles @LudivineLebour1 @MoglieQuintrec @karine_renaudin #AKI #ANCA #VisualAbstract https://t.co/oy9m6wU1OH
-
-
Mashup Score: 0FDA Approves Avacopan to Treat ANCA-associated Vasculitis - 3 year(s) ago
The FDA has approved avacopan (Tavneos) as an adjunctive treatment for severe ANCA-associated vasculitis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The U.S. Food and Drug Administration approved avacopan #Tavneos for adult patients with severe active anti-neutrophil cytoplasmic autoantibody #ANCA -associated vasculitis. @US_FDA FDA US FDA News @FDAMedWatch @chemocentryxinc ChemoCentryx ChemoCentryx https://t.co/lFllsh3xvk
-
-
Mashup Score: 1FDA Approves Avacopan to Treat ANCA-associated Vasculitis - 3 year(s) ago
The FDA has approved avacopan (Tavneos) as an adjunctive treatment for severe ANCA-associated vasculitis.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The U.S. Food and Drug Administration approved avacopan #Tavneos for adult patients with severe active anti-neutrophil cytoplasmic autoantibody #ANCA -associated vasculitis. @US_FDA FDA US FDA News @FDAMedWatch @chemocentryxinc ChemoCentryx ChemoCentryx https://t.co/lFllsh3xvk
-
#EULAR recommendations for management of #ANCA-associated vasculitis granulomatosis polyangiitis (GPA), microscopic polyangiitis (MPA) ➡️ Therapy for severe AAV is #cyclophosphamide or #rituximab plus glucocorticoids 👉🏼https://t.co/MVrql0au27 Via Prof Raashid Luqmani #BSR23 https://t.co/QimOnOvGTu